Rezzayo (rezafungin): new drug application

Juanary 24,2023

The Antimicrobial Drugs Advisory Committee (AMDAC), in ten meeting  solidly agreed that the benefits of Rezzayo (rezafungin), submitted by Cidara Therapeutics, Inc, outweigh the risks for adults with candidemia and invasive candidiasis (IC) who have limited or no alternative treatments. Although panelists had reservations about the supporting data for rezafungin, they noted that the drug would be a beneficial option for this patient population.

Additional information are available at the following link.